Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale

被引：33

作者：

Grunwald, Viktor ^{[1
]}

Powles, Thomas ^{[2
]}

Choueiri, Toni K. ^{[3
]}

Hutson, Thomas E. ^{[4
]}

Porta, Camillo ^{[5
,6
]}

Eto, Masatoshi ^{[7
]}

Sternberg, Cora N. ^{[8
]}

Rha, Sun Young ^{[9
]}

He, Cixin S. ^{[10
]}

Dutcus, Corina E. ^{[10
]}

Smith, Alan ^{[10
]}

Dutta, Lea ^{[10
]}

Mody, Kalgi ^{[10
]}

Motzer, Robert J. ^{[11
]}

机构：

[1] Univ Hosp Essen, Clin Hematol Hemostasis Oncol & Stem Cell Transpl, Essen, Germany

[2] Barts Canc Inst, Expt Canc Med, London, England

[3] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA

[4] Baylor Univ, Med Ctr, Urol Oncol Program, Dallas, TX USA

[5] Univ Pavia, Pavia, Italy

[6] IRCCS Ist Clin Sci Maugeri, Div Translat Oncol, Pavia, Italy

[7] Kyushu Univ, Dept Urol, Fukuoka, Fukuoka, Japan

[8] New York Presbyterian, Weill Cornell Med, New York, NY USA

[9] Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea

[10] Eisai Inc, Woodcliff Lake, NJ USA

[11] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA

来源：

FUTURE ONCOLOGY | 2019年 / 15卷 / 09期

关键词：

everolimus; first-line treatment; immuno-oncology; lenvatinib; pembrolizumab; renal cell carcinoma; sunitinib; tyrosine kinase inhibitor; ENDOTHELIAL GROWTH-FACTOR; TYROSINE KINASE INHIBITOR; ANTITUMOR ACTIVITIES; TARGETED THERAPY; MTOR INHIBITORS; CLINICAL-TRIAL; PHASE-II; COMBINATION; E7080; BEVACIZUMAB;

D O I：

10.2217/fon-2018-0745

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: Lenvatinib plus everolimus is approved for the treatment of advanced renal cell carcinoma (RCC) after one prior vascular endothelial growth factor-targeted therapy. Lenvatinib plus pembrolizumab demonstrated promising antitumor activity in a Phase I/II trial of RCC. Methods: We describe the rationale and design of the CLEAR study, a three-arm Phase III trial comparing lenvatinib plus everolimus and lenvatinib plus pembrolizumab versus sunitinib monotherapy for first-line treatment of RCC. Eligible patients must have advanced clear cell RCC and must not have received any prior systemic anticancer therapy. The primary end point is progression-free survival; secondary end points include objective response rate, overall survival, safety, health-related quality of life and pharmacokinetics. Biomarker evaluations are included as exploratory end points.

引用

页码：929 / 941

页数：13

共 50 条

[1] Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Motzer, Robert
Alekseev, Boris
Rha, Sun-Young
Porta, Camillo
Eto, Masatoshi
Powles, Thomas
Gruenwald, Viktor
Hutson, Thomas E.
Kopyltsov, Evgeny
Mendez-Vidal, Maria J.
Kozlov, Vadim
Alyasova, Anna
Hong, Sung-Hoo
Kapoor, Anil
Alonso Gordoa, Teresa
Merchan, Jaime R.
Winquist, Eric
Maroto, Pablo
Goh, Jeffrey C.
Kim, Miso
Gurney, Howard
Patel, Vijay
Peer, Avivit
Procopio, Giuseppe
Takagi, Toshio
Melichar, Bohuslav
Rolland, Frederic
De Giorgi, Ugo
Wong, Shirley
Bedke, Jens
Schmidinger, Manuela
Dutcus, Corina E.
Smith, Alan D.
Dutta, Lea
Mody, Kalgi
Perini, Rodolfo F.
Xing, Dongyuan
Choueiri, Toni K.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (14): : 1289 - 1300
[2] Re: Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Chang, Sam S.
[J]. JOURNAL OF UROLOGY, 2021, 206 (06): : 1518 - 1519
[3] Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study
Eto, Masatoshi
Takagi, Toshio
Kimura, Go
Fukasawa, Satoshi
Tamada, Satoshi
Miura, Yuji
Oya, Mototsugu
Sassa, Naoto
Anai, Satoshi
Nozawa, Masahiro
Sakai, Hideki
Perini, Rodolfo
Yusa, Wataru
Ikezawa, Hiroki
Narita, Tomoyuki
Tomita, Yoshihiko
[J]. CANCER MEDICINE, 2023, 12 (06): : 6902 - 6912
[4] Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Rini, Brian I.
Plimack, Elizabeth R.
Stus, Viktor
Gafanov, Rustem
Hawkins, Robert
Nosov, Dmitry
Pouliot, Frederic
Alekseev, Boris
Soulieres, Denis
Melichar, Bohuslav
Vynnychenko, Ihor
Kryzhanivska, Anna
Bondarenko, Igor
Azevedo, Sergio J.
Borchiellini, Delphine
Szczylik, Cezary
Markus, Maurice
McDermott, Raymond S.
Bedke, Jens
Tartas, Sophie
Chang, Yen-Hwa
Tamada, Satoshi
Shou, Qiong
Perini, Rodolfo F.
Chen, Mei
Atkins, Michael B.
Powles, Thomas
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (12): : 1116 - 1127
[5] PHASE 3 STUDY OF PEMBROLIZUMAB plus BELZUTIFAN plus LENVATINIB OR PEMBROLIZUMAB/QUAVONLIMAB plus LENVATINIB VERSUS PEMBROLIZUMAB plus LENVATINIB AS FIRST-LINE TREATMENT FOR ADVANCED RENAL CELL CARCINOMA
Choueiri, Toni
Plimack, Elizabeth
Powles, Thomas
Voss, Martin
Gurney, Howard
Silverman, Rachel
Perini, Rodolfo
Rodriguez-Lopez, Karla
Rini, Brian
[J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A447 - A447
[6] Phase 3 study of first-line treatment with pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib for advanced renal cell carcinoma (RCC).
Choueiri, Toni K.
Plimack, Elizabeth R.
Powles, Thomas
Voss, Martin H.
Gurney, Howard
Silverman, Rachel Kloss
Perini, Rodolfo F.
Rodriguez-Lopez, Karla
Rini, Brian I.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[7] Re: Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Teh, Jiasian
Narasimhan, Vignesh
Schultz, Stephen
Sathianathen, Niranjan
Murphy, Declan G.
[J]. EUROPEAN UROLOGY, 2019, 76 (01) : 126 - 127
[8] Updated efficacy of lenvatinib (LEN) plus pembrolizumab (PEMBRO) versus sunitinib (SUN) in patients with advanced renal cell carcinoma (aRCC) in the CLEAR study
Porta, Camillo G.
Eto, Masatoshi
Motzer, Robert J.
De Giorgi, Ugo
Buchler, Tomas
Basappa, Naveen S.
Mendez Vidal, Maria Jose
Tjulandin, Sergei
Park, Se Hoon
Melichar, Bohuslav
Hutson, Thomas
Alemany, Carlos
McGregor, Bradley
He, Cixin Steven
Perini, Rodolfo
Mody, Kalgi
McKenzie, Jodi
Ebaid, Basant
Choueiri, Toni
[J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 122 - 123
[9] First-Line Lenvatinib Plus Pembrolizumab or Everolimus versus Sunitinib for Advanced Renal Cell Carcinoma: A United States-Based Cost-Effectiveness Analysis
Zhu, Youwen
Liu, Kun
Ding, Dong
Peng, Libo
[J]. CLINICAL GENITOURINARY CANCER, 2023, 21 (03) : 417e1 - 417e10
[10] Lenvatinib Combined With Pembrolizumab or Everolimus Lengthens Survival in Advanced Renal Cell Carcinoma
Motzer, Robert J.
Choueiri, Toni
[J]. ONCOLOGY-NEW YORK, 2021, 35 (04): : 220 - 222

← 1 2 3 4 5 →